For informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.
Price · 1Y
$24.77
Thesis
Viking Therapeutics is developing VK2735, a dual GLP-1/GIP receptor agonist, in both injectable and oral formulations. As a pure-play, its outlook is tied to the clinical progression of this metabolic candidate.
Catalysts
- VK2735 injectable clinical trial readouts
- VK2735 oral formulation data
- Advancement into later-stage development
Recent events
Material filings, federal awards, and regulatory activity. Impact is scored against market cap.
- Nov 16Trial initiationClinicalTrials.gov
Phase 3 trial NCT07868939 (SUNRISE 2) of oral VK2735 for weight management in T2DM now recruiting.
- Nov 16Trial initiationClinicalTrials.gov
Phase 3 SUNRISE 1 trial (NCT07868835) of oral VK2735 for weight management updated to recruiting status.
- Oct 28Financial resultsSEC
VKTX 8-K (items 2.02, 9.01) reports results of operations.
- Oct 16Trial initiationClinicalTrials.gov
Phase 3 trial (SUNRISE 2) of oral VK2735 for weight management in Type 2 diabetes listed as not yet recruiting.
- Oct 16Trial initiationClinicalTrials.gov
Phase 3 trial NCT07868835 (SUNRISE 1) for oral VK2735 weight management listed as not yet recruiting.
- Oct 9Trial initiationClinicalTrials.gov
Phase 3 trial (SUNRISE 1) of oral VK2735 for weight management listed as not yet recruiting.
- Oct 9Trial initiationClinicalTrials.gov
Phase 3 trial NCT07868939 (SUNRISE 2) of oral VK2735 for weight management in T2DM updated to not yet recruiting.
- Sep 29Trial initiationClinicalTrials.gov
Viking Therapeutics initiates Phase 1 trial of VK3019 in overweight and obese adults (NCT07846033).